Analysts think KOD stock price could increase by 60%
Mar 12, 2026, 11:25 AM
-7.45%
What does KOD do
Kodiak Sciences, a clinical-stage biopharmaceutical company based in Palo Alto, develops therapeutics for retinal diseases, including tarcocimab and KSI-501, using its innovative ABC Platform. The company went public on October 4, 2018, and employs 107 staff.
7 analysts think KOD stock price will increase by 59.96%. The current median analyst target is $39.27 compared to a current stock price of $24.55. The lowest analysts target is $14.14 and the highest analyst target is $52.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.